Breaking News

Friday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Selecta positioned for 50%-100% rally on positive data, says Cantor Fitzgerald » 07:47
02/21/20
02/21
07:47
02/21/20
07:47
SELB

Selecta Biosciences

$4.29 /

-0.2 (-4.45%)

, HZNP

Horizon Therapeutics

$36.05 /

-0.03 (-0.08%)

After hosting investor…

After hosting investor meetings with Selecta Biosciences (SELB) management, Cantor Fitzgerald analyst Elaina Merle continues to see a high likelihood that the COMPARE study is positive. The shares are positioned for a 50% to 100% plus move up on statistical significance superiority in COMPARE, Merle tells investors in a research note. Selecta's SEL-212 is well powered to show superiority versus Horizon Therapeutics' (HZNP) Krystexxa in the mid-year readout, says the analyst. Further, she sees further optionality from gene therapy, which the company has guided to enter the clinic this year in collaboration with AskBio. Merle reiterates an Overweight rating on Selecta shares with a $10 price target.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Thursday
Initiation
Fly Intel: Top five analyst initiations » 10:07
02/20/20
02/20
10:07
02/20/20
10:07
EIDX

Eidos Therapeutics

$52.13 /

+0.14 (+0.27%)

, ITCI

Intra-Cellular

$24.60 /

+0.6 (+2.50%)

, ABUS

Arbutus Biopharma

$3.46 /

+0.19 (+5.81%)

, HCM

Hutchison China MediTech

$27.74 /

+0.3 (+1.09%)

, SNDR

Schneider National

$21.78 /

-0.17 (-0.77%)

Catch up on today's…

Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Eidos Therapeutics (EIDX) initiated with a Buy at Guggenheim. 2. Intra-Cellular (ITCI) initiated with an Outperform at Evercore ISI. 3. Arbutus Biopharma (ABUS) initiated with an Outperform at Baird. 4. Hutchison China MediTech (HCM) initiated with a Buy at Goldman Sachs. 5. Schneider National (SNDR) initiated with a Market Perform at Cowen. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Initiation
Hutchison China MediTech initiated with a Buy at Goldman Sachs » 05:03
02/20/20
02/20
05:03
02/20/20
05:03
HCM

Hutchison China MediTech

$27.44 /

+0.06 (+0.22%)

Goldman Sachs analyst…

Goldman Sachs analyst Paul Choi initiated coverage of Hutchison China MediTech with a Buy rating and $38 price target. The company is on the cusp of a transition that will drive "significant value accretion" over the near-term with key milestones expected in 2020 and 2021, Choi tells investors in a research note. Global partnerships validate the quality of Hutchison's discovery engine, but increasing independence will shape the trajectory from here, he adds.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Wednesday
Hot Stocks
Enzo Biochem's board increase proposal receives negative recommendation from ISS » 17:22
02/19/20
02/19
17:22
02/19/20
17:22
ENZ

Enzo Biochem

$2.25 /

+ (+0.00%)

Enzo Biochem shareholders…

Enzo Biochem shareholders Harbert Discovery Fund and Harbert Discovery Co-Investment Fund I, collectively HDF, the beneficial owners of more than 11.8% of the outstanding shares of Enzo Biochem, announced that proxy advisory firm ISS has recommended that shareholders vote against Enzo's proposal to amend its bylaws in order to increase the size of the Board and re-nominate Barry Weiner. Enzo's delayed 2019 Annual Meeting of Shareholders is scheduled for February 25. The analysis from ISS states, among other things: "A deeper review reveals modifications that appear to constitute an eleventh-hour attempt to salvage a board seat for Weiner in light of what appears to be strong shareholder support for the dissident nominees. Given the timing of the announcement - three days before the scheduled Annual General Meeting and after an apparently strong showing of support for the dissident nominees -, the board's assertion that it is somehow shareholder friendly is not only misleading, but arguably deceptive. (...) "The proposed increase in board size appears to be a late-stage entrenchment maneuver in response to what appears to have been robust support for the dissident campaign... (...) Given that it is unclear how this would be a net benefit to shareholders, support AGAINST this proposal is warranted".

ShowHide Related Items >><<
Hot Stocks
Enzo Biochem announces data indicating SK1-I reduced Lupus parameters published » 08:37
02/19/20
02/19
08:37
02/19/20
08:37
ENZ

Enzo Biochem

$2.25 /

+0.03 (+1.35%)

Enzo Biochem announced…

Enzo Biochem announced the publication of a study in The FASEB Journal by academic researchers that shows drug candidate SK1-I, the company's proprietary Sphingosine Kinase 1 inhibitor, markedly reduced Lupus-associated parameters in a recognized, chemically-induced animal model of Systemic Lupus Erythematosus, commonly known as Lupus. This treatment resulted in reductions in interferon, or IFN, signature, pDC activation and glomerulonephritis, the inflammation of the filtration units of the kidney. Significantly, SK1-I was not only effective when administered simultaneously with the chemical induction of Lupus in this model, but was also effective when administered 30 days after the chemical induction of the disorder. In further confirmation that the effects of SK1-I in the Lupus model are the result of inhibiting the enzyme Sphingosine Kinase 1, the effects were mirrored by genetic deletion of the enzyme. These results suggest that SK1-I may have potential in the treatment of Lupus.

ShowHide Related Items >><<
Tuesday
Conference/Events
Pulse Biosciences holds a pharmaceutical update conference call » 16:25
02/18/20
02/18
16:25
02/18/20
16:25
PLSE

Pulse Biosciences

$8.12 /

-0.41 (-4.81%)

Management provides an…

Management provides an update on the Company's FDA 510(k) submission for the CellFX System in dermatology on a conference call to be held on February 18 at 5 pm. Webcast Link

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Amarin rises as Citi says Buy on selloff, accelerating Vascepa sales » 11:20
02/18/20
02/18
11:20
02/18/20
11:20
AMRN

Amarin

$17.93 /

+0.3 (+1.70%)

, RDY

Dr. Reddy's

$45.37 /

-0.13 (-0.29%)

, HKMPF

Hikma Pharmaceuticals

$0.00 /

+ (+0.00%)

Shares of Amarin (AMRN)…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

On The Fly
Tesla target hikes headline today's top Wall Street calls » 10:33
02/18/20
02/18
10:33
02/18/20
10:33
TSLA

Tesla

$852.88 /

+52.93 (+6.62%)

, AAPL

Apple

$317.46 /

-7.45 (-2.29%)

, AMRN

Amarin

$18.02 /

+0.39 (+2.21%)

, CTL

CenturyLink

$13.25 /

-0.65 (-4.68%)

, AEO

American Eagle

$14.66 /

-0.17 (-1.15%)

, M

Macy's

$16.62 /

-0.04 (-0.24%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Upgrade
Fly Intel: Top five analyst upgrades » 10:15
02/18/20
02/18
10:15
02/18/20
10:15
AMRN

Amarin

$18.06 /

+0.43 (+2.44%)

, DUK

Duke Energy

$102.02 /

+0.67 (+0.66%)

, KN

Knowles

$18.13 /

+0.4 (+2.26%)

, BC

Brunswick

$64.94 /

-0.095 (-0.15%)

, WWE

WWE

$46.27 /

+1.33 (+2.96%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Amarin (AMRN) upgraded to Buy from Neutral at Citi with analyst Joel Beatty saying with the stock trading 27% lower since November, now is an attractive time to buy. 2. Duke Energy (DUK) upgraded to Outperform from Neutral at Credit Suisse with analyst Michael Weinstein sayin he sees last year's $2.5B equity forward that was issued to support any contingency associated with the Atlantic Coast Pipeline project as providing Duke Energy the flexibility to fund additional accretive organic growth in the meantime. 3. Knowles (KN) upgraded to Overweight from Neutral at Piper Sandler with analyst Harsh Kumar saying he expects the operational issues affecting March quarter gross margin and the demand concerns surrounding Chinese handsets to ease entering the June 2020 quarter. 4. Brunswick (BC) upgraded to Outperform from Market Perform at Raymond James with analyst Joseph Altobello saying Brunswick has emerged as the pure-play leader in the U.S. marine industry with a balanced portfolio across boats, engines and parts and accessories. 5. WWE (WWE) upgraded to Overweight from Equal Weight at Consumer Edge. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Conference/Events
Noble Capital to hold a conference » 07:50
02/18/20
02/18
07:50
02/18/20
07:50
UAVS

Ageagle Aerial Systems

$0.55 /

-0.0019 (-0.35%)

, CLBS

Caladrius

$2.88 /

+0.13 (+4.73%)

, CMTL

Comtech

$33.54 /

-0.67 (-1.96%)

, COCP

Cocrystal Pharma

$0.54 /

-0.0109 (-1.98%)

, CPST

Capstone Turbine

$2.76 /

-0.17 (-5.80%)

, LCTX

Lineage Cell Therapeutics

$1.53 /

+0.01 (+0.66%)

, XBIO

Xenetic

$1.21 /

-0.07 (-5.47%)

, SPI

SPI Energy

$1.33 /

+0.005 (+0.38%)

, ESEA

Euroseas

$3.20 /

+0.07 (+2.24%)

16th Annual NobleCon…

16th Annual NobleCon Investor Conference will be held in Hollywood, FL on February 16-18.

ShowHide Related Items >><<
03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.